The global Lipid Nanoparticles Market was valued at US$ 789.0 million in 2022 and is expected to reach US$ 3.3 billion by 2033. Solid lipid nanoparticles, with around 64.8% of value share in 2022, dominated the market. The market is further projected to surge at a CAGR of 14.2% in the estimated period 2023 to 2033.
| Attributes | Key Insights |
|---|---|
| Lipid Nanoparticles Market Size (2022A) | US$ 789.0 million |
| Estimated Lipid Nanoparticles Market Size (2023E) | US$ 877.8 million |
| Projected Lipid Nanoparticles Market Size (2033F) | US$ 3.3 billion |
| Value-based Lipid Nanoparticles Market CAGR (2023 to 2033) | 14.2% |
Lipid nanoparticles are expected to offer advantages such as improved skin penetration and controlled release of active ingredients. This is set to result in better performance and efficacy of cosmetic and personal care products. Cosmetic products made of lipid nanoparticles are expected to be in high demand as these work as an anti-aging treatment and shield against radiation damage to the skin.
Due to their antioxidant properties, cosmetics companies are using naturally occurring antioxidants such as carotenoids, retinoids, and tocopherols as skincare and therapeutic active ingredients in their products. An anti-inflammatory and irritation-fighting cosmetic formulation based on lipid nanoparticles and antioxidants holds significant potential for treating skin conditions such as atopic dermatitis and psoriasis.
Over free drug delivery, nanoparticle-based drug delivery is expected to improve efficacy and drug accumulation. Circulation, half-life, surface features, size, and the level of angiogenesis are all factors that are anticipated to influence the distribution of nanoparticles within tumor tissues.
The evolution of new laws, extra funding possibilities, and increased public-private collaborations are set to drive the expansion of creative, collaborative research prospects in liposomal medicinal formulations. There has been a significant shift in emphasis toward creating lipid-based excipients that are dispersible, flexible, and multi-functional. In the forecast period, the demand for these excipients and oral formulations is projected to be driven by the constant focus on unmet medical needs in lipid-based medications.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global lipid nanoparticles market held around 16.0% of the total US$ 4.9 billion of the global pharmaceutical lipid market in 2022. Nanoparticles have qualitatively different physicochemical properties than micron-sized particles, which can result in altered body distribution, penetration of the blood-brain barrier, and activation of blood coagulation pathways.
The risks posed by utilizing nanoparticles for medicine administration go beyond the risks posed by chemicals in traditional delivery matrices. For nanoparticles, knowledge of particle toxicity as derived via inhalation toxicity demonstrates how to evaluate the possible risks of nanoparticles.
Both customized medicine and nanomedicine are relatively recent concepts in medical practice. Nanomedicine is expected to be integrated into diagnostic and therapeutic instruments to address a wide range of medical diseases.
Personalized medicine, or precision medicine, is also anticipated to individualize/customize therapeutic management based on the patient's characteristics to overcome blanket treatment. It is projected to be only effective in a subset of patients, leaving others with either ineffective treatment or treatment that causes significant toxicity. Due to these factors, the global lipid nanoparticles market is projected to surge at a CAGR of 14.2% in the forecast period.
During the historical period, the pharmaceutical industry witnessed rapid growth in outsourcing pharmaceutical services. This expansion is mainly attributed to the rising demand for pharmaceutical lipids.
Due to technological and regular operational hurdles, a growing number of pharmaceutical firms are opting to outsource their respective lipid manufacturing operations to specialist service providers. Several advantages of using CDMOs for lipid production are anticipated to push their demand.
For instance, contracting a supplier for medical-grade lipids would allow sponsors to take advantage of new technology (available through the service provider), access higher capacities, and gain better operational flexibility. There are now several contract manufacturers and technology suppliers claiming to be able to produce lipid-based drug delivery systems (such as liposomes/lipid nanoparticles) and lipid excipients.
| Attributes | Key Factors |
|---|---|
| Lipid Nanoparticles Market Trends |
|
| Growth Hindrances |
|
| Upcoming Opportunities |
|
Principal Consultant
In the table below, the CAGRs of the top 6 countries are given for the review period 2023 to 2033. The United Kingdom and India are expected to remain dominant by exhibiting CAGRs of 19.9% and 18.6%, respectively. Japan, China, and the United States are further anticipated to follow with CAGRs of 17.7%, 15.6%, and 15.2%, respectively.
| Countries | Value CAGR |
|---|---|
| United States | 15.2% |
| Germany | 14.5% |
| United Kingdom | 19.9% |
| Japan | 17.7% |
| China | 15.6% |
| India | 18.6% |
The United States occupied a 29.0% value share in the global lipid nanoparticles market in 2022, and expenditure on lipid nanoparticles in 2022 was US$ 228.4 million. The country boasts a thriving biotechnology and pharmaceutical sector.
It is also the home to several key pharmaceutical companies, start-ups, and research institutions. This ecosystem fosters innovation in drug delivery technologies, including lipid nanoparticles.
The United States invests heavily in research and development from the public and private sectors. Government agencies such as the National Institutes of Health (NIH) and the National Science Foundation (NSF) provide substantial funding for research in areas, including drug delivery systems, which involve lipid nanoparticles. The United States' high incidence of chronic diseases and emergency visits positions it as a critical market for lipid nanoparticles.
Germany held a 20.2% value share in Europe in 2022, and expenditure on lipid nanoparticles in the same year was US$ 33.9 million. Thanks to Germany's strategic location in the continent, companies have access to a sizable and diverse Europe market. This benefits clinical trials and commercialization efforts, enabling businesses to reach a broad customer base.
Germany also benefits from an administrative system that permits streamlined approvals in the European Union (EU) as a member of the EU. Lipid nanoparticle-based medications and therapies are heavily regulated and approved by the European Medicines Agency (EMA). Similar to the United States, Germany provides strong intellectual property protection, encouraging businesses to spend on research and development and safeguard their ideas.
In 2022, Japan held a dominant revenue in the East Asia market and contributed around US$ 49.1 million. A solid and innovative pharmaceutical sector exists in Japan. Japan-based businesses have a proven track record of creating and producing pharmaceutical products, which can include lipid nanoparticles for medication delivery.
Japan-based colleges and research facilities are famous for their superior scientific capabilities. Lipid nanoparticle technology is set to improve due to partnerships between academic institutions and private sector businesses in Japan.
Japan also has a robust regulatory system in place for drugs and medical equipment. This regulatory experience can aid the development and approval of medicines and therapies based on lipid nanoparticles.
China’s lipid nanoparticles market is poised to exhibit a CAGR of 15.6% during the assessment period. The country has a burgeoning nanotechnology and medication delivery systems research and development scene. Biotechnology businesses, research organizations, and universities in China are conducting LNP research.
China's government has shown a persistent dedication to advancing life sciences and biotechnology, particularly nanotechnology. Several grant schemes and incentives are available to facilitate research in these fields.
The healthcare industry in China is vast and developing quickly, and there is an increasing need for cutting-edge medication delivery methods. This makes the environment ideal for LNP's growth and commercialization.
China has also demonstrated interest in mRNA vaccine technology, which generally employs lipid nanoparticles for delivery, and has actively participated in vaccine expansion. This encounter can have inspired more LNP research and knowledge.
China is an essential player in the worldwide clinical trials landscape. Several multinational pharmaceutical firms are conducting clinical trials in China, allowing LNPs to be tested on different patient groups.
The table below signifies leading sub-categories under application and product categories in the lipid nanoparticles market. Therapeutics are expected to dominate the market for lipid nanoparticles by exhibiting a 16.6% CAGR in the evaluation period. Under the product category, the solid lipid nanoparticles segment is projected to lead the global market at a 15.3% CAGR.
| Segment | Value CAGR |
|---|---|
| Therapeutics (Application) | 16.6% |
| Pharmaceutical and Biotechnology Companies (End-use) | 16.3% |
| Solid Lipid Nanoparticles (Product) | 15.3% |
By type, solid lipid nanoparticles (SLNs) covered 64.8% of market shares in the world in 2022. The segment is predicted to expand rapidly between 2023 and 2033 in the nanostructured lipid carrier business.
Compared to other lipid-based delivery methods, solid lipid nanoparticles are set to be less prone to problems such as drug leakage, aggregation, or degradation over time. This is mainly because of their intrinsic solid-state stability.
With extensive drug-loading capabilities, SLNs can encapsulate a range of hydrophobic and hydrophilic medicines. The ability to administer a wide range of medicinal chemicals depends on this adaptability, which would spur demand.
The value of therapeutics in the lipid nanoparticles market was US$ 464.9 million, representing a 58.9% share in 2022. Lipid nanoparticles, such as solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), are particularly effective at encapsulating a variety of therapeutic agents.
Their ability to encapsulate agents, such as hydrophobic and hydrophilic pharmaceuticals, peptides, nucleic acids (RNA and DNA), and small molecules is anticipated to aid demand. Improved medication solubility and bioavailability are also projected to push demand.
Lipid nanoparticles are expected to provide encapsulated medications with protection from deterioration, especially for medications vulnerable to enzymatic or chemical disintegration. The shelf life of medicinal formulations is increased as a result, which would spur sales.
The pharmaceutical and biotechnology companies have a considerable presence in the lipid nanoparticles market, accounting for 45.2% of the share in terms of end users in 2022. The segment will likely exhibit a high CAGR of 16.3% over the forecast period. These businesses are primarily concerned with creating novel medications and treatments.
Leading pharmaceutical and biotechnology companies are expected to develop new nanoparticles to provide a flexible platform for delivering several pharmacological substances, including peptides, nucleic acids, small molecules, and biologics. These companies are projected to increase the solubility, stability, and bioavailability of novel substances by utilizing lipid nanoparticles, which will result in more potent medicines.
Pharmaceutical and biotechnology companies can also create medicines directly targeting diseased cells or tissues while reducing systemic adverse effects. They are expected to do so by engineering lipid nanoparticles to enable targeted drug delivery. The advancement of precision medicine and individualized treatments depends heavily on this targeted strategy.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Advancements and partnerships among healthcare providers, research institutes, and tech enterprises would gradually foster cutting-edge innovation. Collaborative efforts among manufacturers are set to boost market expansion and diversify applications.
The lipid nanoparticles market is highly competitive. Key manufacturers constantly innovate and develop novel yet economical product lines to increase their consumer base in emerging regions. Establishing new manufacturing sites is the primary emphasis of key firms seeking to expand their geographic reach.
For instance,
| Attribute | Details |
|---|---|
| Estimated Lipid Nanoparticles Market Revenue (2023) | US$ 877.8 million |
| Projected Lipid Nanoparticles Market Revenue (2033) | US$ 3.3 billion |
| Value-based CAGR (2023 to 2033) | 14.2% |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, United Kingdom, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Thailand, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa. |
| Key Market Segments Covered | Type, Application, End User, Region |
| Key Companies Profiled | Abbott; NOF Corporation; Merck KGaA (Exelead); Evonik Industries AG; Gattefossé; Danaher Corporation (Precision NanoSystems); IOI Oleo GmbH; Genevant Sciences; Croda International Plc (Avanti Polar Lipids, Inc.); Lipoid GmbH; CordenPharma International; Cayman Chemical; ABITEC Corporation |
| Report Coverage | Market Forecast, Competition Intelligence, Market Dynamics and Challenges, Strategic Growth Initiatives |
The market was worth US$ 789.0 million in 2022.
The market is estimated to reach around US$ 877.8 million by 2023.
The global market is expected to reach US$ 3.3 billion by the end of 2033.
The market grew at a CAGR of 9.5% between 2018 and 2022.
The United States contributed around US$ 228.4 million in 2022.
Germany held around 20.2% of the market value share in 2022.
Japan is set to witness a CAGR of 17.7% from 2023 to 2033.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Innovation Trends 4. Value-Added Insights 4.1. Product Usage/Adoption Analysis 4.2. Regulatory Scenario 4.3. PESTEL Analysis 4.4. Porters Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Expenditure 5.1.2. Global Life Expectancy Outlook 5.1.3. Research and Development funding By Region 5.1.4. Research and Development funding By Country 5.2. Forecast Factors - Relevance & Impact 5.2.1. Increasing Application of in Drug Delivery 5.2.2. Increased Number of Product Launches 5.2.3. Increasing Demand for (LNPs) By Pharmaceutical Companies 5.2.4. Rising Healthcare Expenditure 5.2.5. Growing Demand for Sustained-release Formulations 5.2.6. Historic Growth of Key Companies 5.2.7. Pharmaceutical and Biomedical Applications 5.2.8. Consumer Preferences 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand (in Value or Size in US$ million) Analysis 2018 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Value (US$ million) Analysis, 2018 to 2022 6.2. Current and Future Market Value (US$ million) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ million) Analysis By Type, 2018 to 2022 7.3. Current and Future Market Size (US$ million) Analysis and Forecast By Type, 2023 to 2033 7.3.1. Solid Lipid Nanoparticles 7.3.2. Nanostructured Lipid Carriers 7.3.3. Others 7.4. Market Attractiveness Analysis By Type 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ million) By Application, 2018 to 2022 8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Application, 2023 to 2033 8.3.1. Therapeutics 8.3.2. Research 8.4. Market Attractiveness Analysis By Application 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ million) By End User, 2018 to 2022 9.3. Current and Future Market Size (US$ million) Analysis and Forecast By End User, 2023 to 2033 9.3.1. Pharmaceutical & Biotechnology Companies 9.3.2. Academics & Research Centers 9.3.3. Others 9.4. Market Attractiveness Analysis By End User 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ million) Trend Analysis by Region, 2018 to 2022 10.3. Current and Future Market Size (US$ million) Analysis and Forecast by Region, 2023 to 2033 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. East Asia 10.3.5. South Asia 10.3.6. Oceania 10.3.7. Middle East and Africa 10.4. Market Attractiveness Analysis by Region 11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 11.1. Introduction 11.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022 11.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 11.3.1. By Country 11.3.1.1. United States 11.3.1.2. Canada 11.3.2. By Type 11.3.3. By Application 11.3.4. By End User 11.4. Market Attractiveness Analysis 11.4.1. By Country 11.4.2. By Type 11.4.3. By Application 11.4.4. By End User 11.5. Country-Wise Analysis 11.5.1. United States Market Analysis 11.5.1.1. Introduction 11.5.1.2. Market Analysis and Forecast by Market Taxonomy 11.5.1.2.1. By Type 11.5.1.2.2. By Application 11.5.1.2.3. By End User 11.5.2. Canada Market Analysis 11.5.2.1. Introduction 11.5.2.2. Market Analysis and Forecast by Market Taxonomy 11.5.2.2.1. By Type 11.5.2.2.2. By Application 11.5.2.2.3. By End User 12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022 12.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. Brazil 12.3.1.2. Mexico 12.3.1.3. Argentina 12.3.1.4. Rest of Latin America 12.3.2. By Type 12.3.3. By Application 12.3.4. By End User 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Type 12.4.3. By Application 12.4.4. By End User 12.5. Country-Wise Analysis 12.5.1. Brazil Market Analysis 12.5.1.1. Introduction 12.5.1.2. Market Analysis and Forecast by Market Taxonomy 12.5.1.2.1. By Type 12.5.1.2.2. By Application 12.5.1.2.3. By End User 12.5.1.2.4. By Route of Administration 12.5.1.2.5. By End User 12.5.2. Mexico Market Analysis 12.5.2.1. Introduction 12.5.2.2. Market Analysis and Forecast by Market Taxonomy 12.5.2.2.1. By Type 12.5.2.2.2. By Application 12.5.2.2.3. By End User 12.5.2.2.4. By Route of Administration 12.5.2.2.5. By End User 12.5.3. Argentina Market Analysis 12.5.3.1. Introduction 12.5.3.2. Market Analysis and Forecast by Market Taxonomy 12.5.3.2.1. By Type 12.5.3.2.2. By Application 12.5.3.2.3. By End User 12.5.3.2.4. By Route of Administration 12.5.3.2.5. By End User 13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022 13.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. Germany 13.3.1.2. Italy 13.3.1.3. France 13.3.1.4. United Kingdom 13.3.1.5. Spain 13.3.1.6. BENELUX 13.3.1.7. Nordic Countries 13.3.1.8. Russia 13.3.1.9. Rest of Europe 13.3.2. By Type 13.3.3. By Application 13.3.4. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Type 13.4.3. By Application 13.4.4. By End User 13.5. Country-Wise Analysis 13.5.1. Germany Market Analysis 13.5.1.1. Introduction 13.5.1.2. Market Analysis and Forecast by Market Taxonomy 13.5.1.2.1. By Type 13.5.1.2.2. By Application 13.5.1.2.3. By End User 13.5.2. Italy Market Analysis 13.5.2.1. Introduction 13.5.2.2. Market Analysis and Forecast by Market Taxonomy 13.5.2.2.1. By Type 13.5.2.2.2. By Application 13.5.2.2.3. By End User 13.5.3. France Market Analysis 13.5.3.1. Introduction 13.5.3.2. Market Analysis and Forecast by Market Taxonomy 13.5.3.2.1. By Type 13.5.3.2.2. By Application 13.5.3.2.3. By End User 13.5.4. United Kingdom Republic Market Analysis 13.5.4.1. Introduction 13.5.4.2. Market Analysis and Forecast by Market Taxonomy 13.5.4.2.1. By Type 13.5.4.2.2. By Application 13.5.4.2.3. By End User 13.5.5. Spain Republic Market Analysis 13.5.5.1. Introduction 13.5.5.2. Market Analysis and Forecast by Market Taxonomy 13.5.5.2.1. By Type 13.5.5.2.2. By Application 13.5.5.2.3. By End User 13.5.6. BENELUX Market Analysis 13.5.6.1. Introduction 13.5.6.2. Market Analysis and Forecast by Market Taxonomy 13.5.6.2.1. By Type 13.5.6.2.2. By Application 13.5.6.2.3. By End User 13.5.7. Nordic Countries Market Analysis 13.5.7.1. Introduction 13.5.7.2. Market Analysis and Forecast by Market Taxonomy 13.5.7.2.1. By Type 13.5.7.2.2. By Application 13.5.7.2.3. By End User 13.5.8. Russia Market Analysis 13.5.8.1. Introduction 13.5.8.2. Market Analysis and Forecast by Market Taxonomy 13.5.8.2.1. By Type 13.5.8.2.2. By Application 13.5.8.2.3. By End User 13.5.9. No 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022 14.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. China 14.3.1.2. Japan 14.3.1.3. South Korea 14.3.2. By Type 14.3.3. By Application 14.3.4. By End User 14.3.5. By Route of Administration 14.3.6. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Type 14.4.3. By Application 14.4.4. By End User 14.4.5. By Route of Administration 14.4.6. By End User 14.5. Country-Wise Analysis 14.5.1. China Market Analysis 14.5.1.1. Introduction 14.5.1.2. Market Analysis and Forecast by Market Taxonomy 14.5.1.2.1. By Type 14.5.1.2.2. By Application 14.5.1.2.3. By End User 14.5.2. Japan Market Analysis 14.5.2.1. Introduction 14.5.2.2. Market Analysis and Forecast by Market Taxonomy 14.5.2.2.1. By Type 14.5.2.2.2. By Application 14.5.2.2.3. By End User 14.5.3. South Korea Market Analysis 14.5.3.1. Introduction 14.5.3.2. Market Analysis and Forecast by Market Taxonomy 14.5.3.2.1. By Type 14.5.3.2.2. By Application 14.5.3.2.3. By End User 15. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022 15.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Indonesia 15.3.1.3. Malaysia 15.3.1.4. Thailand 15.3.1.5. Rest of South Asia 15.3.2. By Type 15.3.3. By Application 15.3.4. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Type 15.4.3. By Application 15.4.4. By End User 15.5. Country-Wise Analysis 15.5.1. India Market Analysis 15.5.1.1. Introduction 15.5.1.2. Market Analysis and Forecast by Market Taxonomy 15.5.1.2.1. By Type 15.5.1.2.2. By Application 15.5.1.2.3. By End User 15.5.1.2.4. By Route of Administration 15.5.1.2.5. By End User 15.5.2. Indonesia Market Analysis 15.5.2.1. Introduction 15.5.2.2. Market Analysis and Forecast by Market Taxonomy 15.5.2.2.1. By Type 15.5.2.2.2. By Application 15.5.2.2.3. By End User 15.5.2.2.4. By Route of Administration 15.5.2.2.5. By End User 15.5.3. Malaysia Market Analysis 15.5.3.1. Introduction 15.5.3.2. Market Analysis and Forecast by Market Taxonomy 15.5.3.2.1. By Type 15.5.3.2.2. By Application 15.5.3.2.3. By End User 15.5.3.2.4. By Route of Administration 15.5.3.2.5. By End User 15.5.4. Thailand Market Analysis 15.5.4.1. Introduction 15.5.4.2. Market Analysis and Forecast by Market Taxonomy 15.5.4.2.1. By Type 15.5.4.2.2. By Application 15.5.4.2.3. By End User 15.5.4.2.4. By Route of Administration 15.5.4.2.5. By End User 16. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022 16.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. Australia 16.3.1.2. New Zealand 16.3.2. By Type 16.3.3. By Application 16.3.4. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Type 16.4.3. By Application 16.4.4. By End User 16.5. Country-Wise Analysis 16.5.1. Australia Market Analysis 16.5.1.1. Introduction 16.5.1.2. Market Analysis and Forecast by Market Taxonomy 16.5.1.2.1. By Type 16.5.1.2.2. By Application 16.5.1.2.3. By End User 16.5.2. New Zealand Market Analysis 16.5.2.1. Introduction 16.5.2.2. Market Analysis and Forecast by Market Taxonomy 16.5.2.2.1. By Type 16.5.2.2.2. By Application 16.5.2.2.3. By End User 17. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2018 to 2022 17.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. GCC Countries 17.3.1.2. Türkiye 17.3.1.3. South Africa 17.3.1.4. Rest of Middle East and Africa 17.3.2. By Type 17.3.3. By Application 17.3.4. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Type 17.4.3. By Application 17.4.4. By End User 17.5. Country-Wise Analysis 17.5.1. GCC Countries Market Analysis 17.5.1.1. Introduction 17.5.1.2. Market Analysis and Forecast by Market Taxonomy 17.5.1.2.1. By Type 17.5.1.2.2. By Application 17.5.1.2.3. By End User 17.5.2. Turkey Market Analysis 17.5.2.1. Introduction 17.5.2.2. Market Analysis and Forecast by Market Taxonomy 17.5.2.2.1. By Type 17.5.2.2.2. By Application 17.5.2.2.3. By End User 17.5.3. South Africa Market Analysis 17.5.3.1. Introduction 17.5.3.2. Market Analysis and Forecast by Market Taxonomy 17.5.3.2.1. By Type 17.5.3.2.2. By Application 17.5.3.2.3. By End User 18. Market Structure Analysis 18.1. Market Analysis by Tier of Companies 18.2. Market Share Analysis of Top Players 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Competition Deep Dive 19.3.1. NOF corporation 19.3.1.1. Overview 19.3.1.2. Key Financials 19.3.1.3. SWOT Analysis 19.3.1.4. Key Developments 19.3.1.5. Sales Footprint 19.3.1.6. Strategy Overview 19.3.1.6.1. Marketing Strategy 19.3.1.6.2. Channel Strategy 19.3.2. Merck KGaA (Exelead) 19.3.2.1. Overview 19.3.2.2. Key Financials 19.3.2.3. SWOT Analysis 19.3.2.4. Key Developments 19.3.2.5. Sales Footprint 19.3.2.6. Strategy Overview 19.3.2.6.1. Marketing Strategy 19.3.2.6.2. Channel Strategy 19.3.3. Evonik Industries AG 19.3.3.1. Overview 19.3.3.2. Key Financials 19.3.3.3. SWOT Analysis 19.3.3.4. Key Developments 19.3.3.5. Sales Footprint 19.3.3.6. Strategy Overview 19.3.3.6.1. Marketing Strategy 19.3.3.6.2. Channel Strategy 19.3.4. Gattefossé 19.3.4.1. Overview 19.3.4.2. Key Financials 19.3.4.3. SWOT Analysis 19.3.4.4. Key Developments 19.3.4.5. Sales Footprint 19.3.4.6. Strategy Overview 19.3.4.6.1. Marketing Strategy 19.3.4.6.2. Channel Strategy 19.3.5. Danaher Corporation (Precision NanoSystems) 19.3.5.1. Overview 19.3.5.2. Key Financials 19.3.5.3. SWOT Analysis 19.3.5.4. Key Developments 19.3.5.5. Sales Footprint 19.3.5.6. Strategy Overview 19.3.5.6.1. Marketing Strategy 19.3.5.6.2. Channel Strategy 19.3.6. IOI Oleo GmbH 19.3.6.1. Overview 19.3.6.2. Key Financials 19.3.6.3. SWOT Analysis 19.3.6.4. Key Developments 19.3.6.5. Sales Footprint 19.3.6.6. Strategy Overview 19.3.6.6.1. Marketing Strategy 19.3.6.6.2. Channel Strategy 19.3.7. Genevant Sciences 19.3.7.1. Overview 19.3.7.2. Key Financials 19.3.7.3. SWOT Analysis 19.3.7.4. Key Developments 19.3.7.5. Sales Footprint 19.3.7.6. Strategy Overview 19.3.7.6.1. Marketing Strategy 19.3.7.6.2. Channel Strategy 19.3.8. Croda International Plc (Avanti Polar Lipids, Inc.) 19.3.8.1. Overview 19.3.8.2. Key Financials 19.3.8.3. SWOT Analysis 19.3.8.4. Key Developments 19.3.8.5. Sales Footprint 19.3.8.6. Strategy Overview 19.3.8.6.1. Marketing Strategy 19.3.8.6.2. Channel Strategy 19.3.9. Lipoid GmbH 19.3.9.1. Overview 19.3.9.2. Key Financials 19.3.9.3. SWOT Analysis 19.3.9.4. Key Developments 19.3.9.5. Sales Footprint 19.3.9.6. Strategy Overview 19.3.9.6.1. Marketing Strategy 19.3.9.6.2. Channel Strategy 19.3.10. CordenPharma International 19.3.10.1. Overview 19.3.10.2. Key Financials 19.3.10.3. SWOT Analysis 19.3.10.4. Key Developments 19.3.10.5. Sales Footprint 19.3.10.6. Strategy Overview 19.3.10.6.1. Marketing Strategy 19.3.10.6.2. Channel Strategy 19.3.11. Cayman Chemical 19.3.11.1. Overview 19.3.11.2. Key Financials 19.3.11.3. SWOT Analysis 19.3.11.4. Key Developments 19.3.11.5. Sales Footprint 19.3.11.6. Strategy Overview 19.3.11.6.1. Marketing Strategy 19.3.11.6.2. Channel Strategy 19.3.12. ABITEC Corporation 19.3.12.1. Overview 19.3.12.2. Key Financials 19.3.12.3. SWOT Analysis 19.3.12.4. Key Developments 19.3.12.5. Sales Footprint 19.3.12.6. Strategy Overview 19.3.12.6.1. Marketing Strategy 19.3.12.6.2. Channel Strategy 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Lipid Nanoparticles Market
